Interestingly, the natural compound Brustatol was recently found to inhibit NRF2 in cells and to promote tumor sensitization to chemotherapy in vivo [91], suggesting that NRF2 is druggable and that using an NRF2 antagonist may be a feasible therapeutic strategy. Here, NFE2L2 is linked to neoplasm.